TIGIT and acute myeloid leukemia: Moreover, both ligands of TIGIT, PVRL2 (CD112) and PVR (CD155) were also reported to be upregulated on AML blasts at relapse after allo-HCT compared to the level at diagnosis, which was significantly associated with poorer clinical outcome [17, 58, 62].